Merck, Lilly Vow To Press On With CETP, Despite Dalcetrapib Disaster

Early termination of a large outcomes study of Roche’s CETP inhibitor dalcetrapib raises doubts about others in the class. Some analysts speculate that Eli Lilly may opt not to continue with its evacetrapib, but the company says it remains committed.